Present and Emerging Therapies for Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections: Focus on Iclaprim
Autor: | Tiffany H. Bach, Donald I. Hsu, Mark Bounthavong |
---|---|
Rok vydání: | 2011 |
Předmět: |
medicine.medical_specialty
business.industry Pharmacy medicine.disease_cause Antimicrobial Methicillin-resistant Staphylococcus aureus Trimethoprim Multiple drug resistance Staphylococcus aureus medicine Iclaprim General Earth and Planetary Sciences Intensive care medicine business General Environmental Science medicine.drug New drug application |
Zdroj: | Clinical Medicine Reviews in Therapeutics. 3:191-201 |
ISSN: | 1179-2558 |
Popis: | The management of skin and soft-tissue infections caused by multidrug resistant Gram-positive organisms, specifically methicillin-resistant Staphylococcus aureus (MRSA), continues to be a significant challenge for clinicians. Iclaprim is a diaminopyrimidine that has shown potent activity against various Gram-positive organisms, including MRSA, with limited Gram-negative activity similar to that of trimethoprim. Iclaprim has completed two Phase III trials with a submission of New Drug Application to the United States Food and Drug Administration (FDA) in 2008. Subsequently, a complete response letter not supporting the approval of iclaprim was released by the FDA. More recently, Acino Holding Ltd. has acquired the shares and data to iclaprim. Pending final draft guidance from the FDA for future studies, iclaprim may have a role in the management of skin and soft-tissue infections. A Medline search of articles through February 2011 and references of selected citations was conducted. Data from abstracts presented at the International Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America annual meetings were also appraised. This article reviews the antimicrobial profile, pharmacokinetic and pharmacodynamic properties, and available clinical data of iclaprim. |
Databáze: | OpenAIRE |
Externí odkaz: |